PDF Basket
Methanotrophs are microorganisms that metabolise methane. They are a subject of great interest in the environmental sector, where the emission of harmful greenhouse gases is a major concern.
The EU-funded CH4BIOVAL project is working to develop new methanotroph strains that can more readily transform methane from the atmosphere into valuable user products. The CH4BIOVAL team is particularly interested in the potential of methanotrophs to produce large amounts of bio-polymers known as polyhydroxyalkanoates (PHAs).
PHAs include a wide range of materials with different physical properties. Some of them are biodegradable and can be used in the production of bioplastics. The mechanical properties and biocompatibility of PHAs can be changed by modifying their surfaces or by combining them with other polymers, enzymes and inorganic materials. This makes possible an even wider range of applications.
CH4BIOVAL researchers are also interested in another methanotroph by-product called ectoine. This is a natural compound produced by several species of bacteria. It is what’s known as a compatible solute, which can be useful as a protective substance. For example, ectoine is used as an active ingredient in skincare and sun protection products, stabilising proteins and other cellular structures and protecting the skin from dryness and UV radiation.
The CH4BIOVAL project is undertaking the isolation of useful methanotroph strains through conventional genetic selective techniques as well as state-of-the-art bioinformatic techniques. The latter involve the detailed analysis and modification of complex biological features based on an in-depth understanding of the genetic codes of selected strains.
By closely studying the metabolic characteristics of specific methanotroph strains, CH4BIOVAL scientists are identifying key genetic modifications that can improve their performance. Thus, the project is enabling both the abatement of an important greenhouse gas and the production of useful bio-consumables.
The project received funding from the EU’s Marie Skłodowska Curie Actions programme.